scholarly journals Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer: A Letter to the Editor

2021 ◽  
pp. 1-2
Author(s):  
Serkan Ergözen ◽  
Tuna Gümüş
Keyword(s):  
Pancreatic Cancer ◽  
Ketogenic Diet ◽  
Hyperbaric Oxygen ◽  
Hyperbaric Oxygen Therapy ◽  
Oxygen Therapy ◽  
Metastatic Pancreatic Cancer ◽  
Survival Outcomes ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer

2019 ◽  
Vol 27 (1) ◽  
pp. 31-39 ◽  
Author(s):  
Mehmet Salih Iyikesici
Keyword(s):  
Pancreatic Cancer ◽  
Overall Survival ◽  
Ketogenic Diet ◽  
Hyperbaric Oxygen ◽  
Hyperbaric Oxygen Therapy ◽  
Oxygen Therapy ◽  
Metastatic Pancreatic Cancer ◽  
Survival Outcomes ◽  
Pancreatic Ductal Carcinoma ◽  
Term Survival

Background: Despite introduction of new chemotherapeutic agents, outcomes of patients with metastatic pancreatic cancer are still poor. Metabolically supported chemotherapy (MSCT) is a novel approach targeting dysregulated energy mechanism of the tumor cell. Objectives: This study aimed to examine the efficacy of metabolically supported administration of chemotherapy combined with ketogenic diet, hyperthermia, and hyperbaric oxygen therapy (HBOT) in patients with metastatic pancreatic cancer. Method: This retrospective observational study included 25 patients with metastatic pancreatic ductal carcinoma (stage IV) who received MSCT (either gemcitabine-based or FOLFIRINOX regimen administered concomitantly with induced hypoglycemia) plus ketogenic diet, hyperthermia, and HBOT combination. Survival outcomes were evaluated. Results: During the mean follow-up duration of 25.4 ± 19.3 months, median overall survival and median progression-free survival were 15.8 months (95% CI, 10.5–21.1) and 12.9 months (95% CI, 11.2–14.6), respectively. Age and gender did not have any effect on overall survival (p > 0.05 for all). Conclusions: MSCT administered together with ketogenic diet, hyperthermia, and HBOT appears to be a viable option with the potential to improve survival outcomes in patients diagnosed with metastatic pancreatic cancer. Further research, particularly with larger comparative clinical trials, is warranted.

scholarly journals RE:nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

2015 ◽  
Vol 107 (9) ◽  
pp. djv204 ◽  
Author(s):  
Lavanniya K. Palani Velu ◽  
Colin W. Steele ◽  
Euan J. Dickson ◽  
C. Ross Carter ◽  
Colin J. McKay ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Phase Iii ◽  
Metastatic Pancreatic Cancer ◽  
Term Survival ◽  
Phase Iii Trial ◽  
Long Term Survival

scholarly journals nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

2015 ◽  
Vol 107 (2) ◽  
pp. dju413-dju413 ◽  
Author(s):  
D. Goldstein ◽  
R. H. El-Maraghi ◽  
P. Hammel ◽  
V. Heinemann ◽  
V. Kunzmann ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Phase Iii ◽  
Metastatic Pancreatic Cancer ◽  
Term Survival ◽  
Phase Iii Trial ◽  
Long Term Survival

Nasal and paranasal sinus mucosal melanoma: Long-term survival outcomes and prognostic factors

2021 ◽  
Vol 42 (6) ◽  
pp. 103070
Author(s):  
Nicholas B. Abt ◽  
Lauren E. Miller ◽  
Tara E. Mokhtari ◽  
Derrick T. Lin ◽  
Jeremy D. Richmon ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Paranasal Sinus ◽  
Mucosal Melanoma ◽  
Survival Outcomes ◽  
Term Survival ◽  
Long Term Survival

Impact of skin invasion on long-term survival outcomes in gingivobuccal complex carcinoma

2020 ◽  
Author(s):  
Smriti Panda ◽  
Rajeev Kumar ◽  
Ashwin Chandran C ◽  
Alok Thakar ◽  
Suresh C. Sharma ◽  
...  
Keyword(s):  
Survival Outcomes ◽  
Term Survival ◽  
Long Term Survival ◽  
Skin Invasion
Sign in / Sign up

Export Citation Format

Share Document